Concepedia

LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study

Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori, T. Kato, Shunichi Sugawara, Keisuke Kirita, Isamu Okamoto, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka,

Annals of Oncology · 2021 · 17 citations · 0 references

DOI

Concepts